<DOC>
	<DOC>NCT00426556</DOC>
	<brief_summary>Phase I: will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer. Phase II: will assess the efficacy and safety of the 10mg daily dose of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer.</brief_summary>
	<brief_title>Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female or male patients ≥ 18 years old with WHO performance status ≤ 1 HER2 overexpressing metastatic breast cancer cells confirmed by histology Progressive disease on prior trastuzumab alone/or in combination with other anticancer agents, or relapsed any time after completion of this therapy (phase l) Patient resistance to trastuzumab and taxanes (Phase ll) Measurable disease according to RECIST (Phase ll) Patients neurologically stable with adequate bone marrow, liver and renal function Patients receiving endocrine therapy for breast cancer ≤ 2 weeks prior to study treatment start Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who have received these ≤ 4 weeks prior to study treatment start or patients who have received lapatinib ≤ 2 weeks prior to study treatment start Patients who have previously received mTOR inhibitors Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Cancer of the breast</keyword>
	<keyword>Human mammary carcinoma</keyword>
	<keyword>HER-2</keyword>
	<keyword>Metastatic</keyword>
	<keyword>everolimus</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>paclitaxel</keyword>
</DOC>